The mutated vaccine peptides comprise two HLA class I-restricted neoepitopes derived from a frameshift insertion in NPM1, which is the most common AML-specific mutation occurring in 35% of all AML patients (38), as well as an HLA class II-restricted neoepitope derived from the AML-specific mutation R140Q in IDH2. The gene discussed is IDH2; the disease is acute myeloid leukemia.